𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses

✍ Scribed by Y. Inoue; N. Hiramatsu; T. Oze; T. Yakushijin; K. Mochizuki; H. Hagiwara; M. Oshita; E. Mita; H. Fukui; M. Inada; S. Tamura; H. Yoshihara; E. Hayashi; A. Inoue; Y. Imai; M. Kato; T. Miyagi; A. Hohsui; H. Ishida; S. Kiso; T. Kanto; A. Kasahara; T. Takehara; N. Hayashi

Book ID
108886333
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
120 KB
Volume
17
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pegylated interferon alpha-2b plus ribav
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
✍ Sanaa M. Kamal; Samer S. El Kamary; Michelle D. Shardell; Mohamed Hashem; Imad N πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 251 KB πŸ‘ 2 views

In patients chronically infected with hepatitis C virus (HCV) genotype 4, the optimum duration of therapy and the predictors of sustained virologic response (SVR) have not been adequately determined. In this study, 358 patients with chronic hepatitis C genotype 4 were randomly assigned to pegylated